{
  "docId": "019de076-6120-7265-9083-1f4de3ff0bf7",
  "docSlug": "b6cd6d5e2a349d701bc6db22946ed621",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 34,
  "pageCount": 52,
  "prevPage": 33,
  "nextPage": 35,
  "slideType": "appendix_methodology",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "Clinical trial design slide detailing patient population, objectives, and cohort structure.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-6120-7265-9083-1f4de3ff0bf7/34",
  "deckHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7",
  "deckJsonHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7.json",
  "deckAnchorHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7#slide-34",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.4,
        "x": 0.07,
        "y": 0.22
      },
      "kind": "list",
      "text": "Phase 1 Dose-Escalation: Patient Population and Objectives",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d1d36289-d2cd-404e-ab0b-e5425e9a7467",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.45,
        "x": 0.42,
        "y": 0.68
      },
      "kind": "paragraph",
      "text": "Phase 2 Objectives: Primary (ORR) and Secondary (DOR, TTR, CBR, PFS, OS, etc.)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4804f289-827f-4124-9cab-07284a295015",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.07,
        "y": 0.82
      },
      "kind": "source-note",
      "text": "1G, 1st generation ALK TKI... Source: Lin J.J. et al., AACR-NCI-EORTC 2023.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c89f4804-4f23-4359-b5c3-af83e4f8f0ef",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.55,
        "x": 0.42,
        "y": 0.22
      },
      "kind": "table",
      "text": "Open-Label Phase 2 Cohorts (Planned) including Cohorts 2a, 2b, 2c, 2d with tumor types and prior therapy requirements",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "79297a40-f087-450b-abdf-f0c1b1d52ccd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "title",
      "text": "ALKove-1: A Global First-in-Human Phase 1/2 Study of NVL-655 in Patients with Advanced ALK-Positive NSCLC and Other Solid Tumors (NCT05384626)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a18a9b2b-a99c-4c54-b3f1-0f544e4e3a1f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "7ad1d87f-6aae-4632-a7a5-f3d491f177d6",
      "evidence": "components include table/data",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 40,
      "from": 29,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "5bd43550-4e7b-49ae-9310-ece1e67e14d2",
      "evidence": "Slides 29-40 present preclinical and clinical trial results for NVL-655.",
      "position": 1,
      "objective": "How can Nuvalent's therapies address the needs of patients with specific cancer mutations?",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.6,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}